Eurand

Eurand NV (Eurand) is a holding company. The company is a specialty pharmaceutical company that develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. It is commercializing a portfolio of products for cystic fibrosis (CF) and gastrointestinal (GI) patients in the United States. As of December 31, 2009, it had two late-stage product candidates, EUR-1073 (beclomethasone) and EUR-1025 (ondansetron), under development in its own portfolio, as well as several other products being developed with partners, including EUR-1000, in collaboration with GlaxoSmithKline (GSK). It has manufacturing and research facilities in the United States, Italy, and France.